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Abstract
The in vivo glucose recovery of subcutaneously implanted nitric oxide (NO)-releasing
microdialysis probes was evaluated in a rat model using saturated NO solutions to steadily release
NO. Such methodology resulted in a constant NO flux of 162 pmol cm-2 s-1 from the probe
membrane over 8 h of perfusion daily. The in vivo effects of enhanced localized NO were
evaluated by monitoring glucose recovery over a 14 d period, with histological analysis thereafter.
A difference in glucose recovery was observed starting at 7 d for probes releasing NO relative to
controls. Histological analysis at 14 d revealed lessened inflammatory cell density at the probe
surface and decreased capsule thickness. Collectively, the results suggest that intermittent
sustained NO release from implant surfaces may improve glucose diffusion for subcutaneously-
implanted sensors by mitigating the foreign body reaction.
INTRODUCTION
The development of implantable glucose sensors that function for extended durations (>1
week) remains elusive primarily due to the foreign body reaction (FBR).1, 2 It is now well
known that the FBR is initiated upon protein adsorption to the implant and culminates with
the formation of a fibrous capsule that sequesters the implant from normal tissue.3-6 The
acute inflammatory response also has a significant effect on the long-term FBR and sensor
function.7 The unfortunate isolation of implanted sensors via the FBR results in decreased
analyte diffusion and analytical performance.3, 8, 9 Achieving extended sensor lifetimes
requires strategies for mitigating the FBR and improving tissue integration. Prior examples
of such strategies include the use of more hydrophilic interfaces, porous coatings, and
surfaces that release pro-angiogenic factors and collagen inhibitory agents.10-12 Although
some improvements in mitigating the FBR have been reported, none have fully resolved the
problems that reduce the sensor lifetime in vivo.
Nitric oxide (NO) is an endogenously produced molecule that acts as a signaling molecule
for cytokine production and has been used to reduce bacterial and platelet adhesion.13-17 In
vivo, active release of NO from a surface has been shown to reduce bacterial adhesion/
infection and improve implant-tissue integration by reducing inflammatory cell infiltration
and collagen encapsulation.18-21 In these studies, release of NO in the first days of
implantation significantly changed both the short- and long-term inflammatory response.18,
21 As such, NO release has the potential to address the difficulties with the FBR associated
with subcutaneous sensor platforms and improve sensor function.
The positive effects of NO release on the FBR have not been assessed with respect to
analyte diffusion through the developing capsule. Our hypothesis is that a thinner capsule
may result in enhanced glucose diffusion thus improving one facet of sensor performance.
Microdialysis allows for direct quantification of glucose diffusion through a membrane
during the FBR. Probes are calibrated by evaluating the extraction efficiency (EE, eq 1) of a
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given analyte.22, 23 The EE is calculated using the concentration of analyte in the perfusate,
dialysate and external solution represented by Cp, Cd and Ce, respectively. The resistances to
mass
(1)
transfer through the membrane (Rm) and dialysate (Rd) are intrinsic to the individual probe
and can be accounted for by in vitro calibration.22 The external resistances to mass transfer
of biofouling (Rbf), encapsulation (Rec) and tissue trauma layers (Rtr) are dependent on the
host response to the probe once implanted, and may change with time.23-26 Glucose
consumption may also be increased in wounded tissue and is thus included in the tissue
trauma term.27
As with subcutaneous sensors, microdialysis probes suffer from diminished analyte
diffusion with longer implantation time.11, 26, 28 Stenken et al. previously examined the
effect of the FBR on analyte diffusion through a microdialysis membrane using magnetic
resonance.29 Others have evaluated membrane composition and the active release of
vascular endothelial growth factor (VEGF) or dexamethasone to alter analyte recovery.11,
26, 29 Neither altering membrane composition nor VEGF or dexamethasone release were
found to adequately circumvent the effect that the FBR has on analyte diffusion. Herein, we
evaluate the influence of NO release on glucose recovery using microdialysis probes
implanted subcutaneously in a rodent model.
EXPERIMENTAL SECTION
Reagents and Materials
Nitrogen, argon and nitric oxide were purchased from AirGas National Welders (Raleigh,
NC). Glucose, glucose oxidase (type VII-S from Aspergillus niger; 168800 units/g) and
horseradish peroxidase (type I, 118 units/mg) were purchased from Sigma (St. Louis, MO).
CMA/20 microdialysis probes with a 10 mm polyarylethersulfone (PAES) membrane and
20-kDa molecular weight cutoff were purchased from CMA Microdialysis Inc (North
Chelmsford, MA). Bioanalytical Systems (West Lafayette, IN) Baby Bee syringe pumps
with 3-syringe brackets, 1 mL Bee Stinger syringes, FEP tubing, PEEK tubing and
microdialysis connectors were used to perfuse microdialysis probes. O-dianisidine
dihydrochloride was obtained from Alfa Aesar (Ward Hill, MA). All other reagents used
were reagent grade and used as received. Phosphate buffered saline (PBS; 10 mM, pH 7.4)
was prepared in-house. PBS saturated with NO (PBS-NO; 1.9 mM NO) was prepared by
purging approximately 20 mL of PBS with argon gas for 20 min to remove oxygen,
followed by nitric oxide gas for 20 min. The solution was stored at 4 °C and used up to 48 h
after saturation.
Measurement of NO release
Real-time NO release was collected using a Sievers 280 Chemiluminescent NO Analyzer
(Boulder, CO). The instrument was calibrated with an atmospheric sample that had been
passed through an NO zero filter and a 25.6 ppm NO gas standard (balance N2). Nitric oxide
release from the microdialysis probe was measured by immersing the probe in deoxygenated
PBS at 37 °C. PBS-NO was then perfused through the probe at 2.0 μL/min with NO carried
from the buffer to the NO Analyzer by a stream of N2 bubbled into the solution at a flow
rate of 80 mL/min.
Nichols et al. Page 2













In Vitro Glucose Recovery
Prior to implantation, microdialysis probes were sterilized with ethylene oxide (gas
treatment), out-gassed for 7 d to facilitate ethylene oxide desorption, and subsequently
hydrated in sterile PBS for 24 h. Probes were then calibrated in a well-stirred solution of
sterile 5.5 mM glucose in PBS at a flow rate of 2.0 μL/min with PBS or PBS-NO as the
perfusate. Three separate dialysates were collected from each probe and stored at -20 °C
until analysis.
Implantation and In Vivo Perfusion of Probes
The animal protocol used in this study was approved by an IACUC committee at Duke
University. Microdialysis probes were implanted into adult male CD rats (150-200 g)
purchased from Charles River Laboratories (Raleigh, NC). Rats were anesthetized with
2-4% isoflurane (v/v in O2). Two probes (one control and one NO-releasing) were then
implanted subcutaneously in 10 rats. Probes were placed bilaterally 5-7 cm caudal to the
scapulae, approximately 2 cm lateral to the spine, in the dorsal subcutis with the probe tips
oriented caudally, and the inflow and outflow percutaneous catheters at the base of the neck.
PEEK or FEP tubing was used with control probes. PEEK tubing was connected to the inlet
of the NO-releasing probes because of its low permeability to NO. Rats were fitted into
infusion harnesses with a spring offset attached to a dual-channel stainless steel swivel on a
counter-balanced swivel mount (Instech Laboratories, Plymouth Meeting, PA) to allow free
movement while continuously perfusing probes. Immediately following implantation and for
each subsequent day, probes were perfused at 2.0 μL/min for 8 h with test (NO gas) or blank
perfusate. During the last 15 min of the perfusion period, one dialysate sample was collected
every 5 min and stored at -20 °C. Immediately following sample collection, a blood sample
was taken via the rat tail vein to allow for blood glucose measurement using a OneTouch
Ultra glucose test strip with a OneTouch Ultra Glucometer (LifeScan, Milpitas, CA).
Explantation and Fixation of Capsules
After 14 d, or after both probes failed, rats were anesthetized with 2-4% isoflurane (v/v in
O2) to allow explantation of the probes with the surrounding tissue capsule intact.
Microdialysis probes were removed from the capsule if still functional and placed in PBS.
The capsules were placed in 10% buffered formalin (v/v) for 24 h and then transferred to
70% ethanol for 24 h prior to their embedment into paraffin. Sections of the paraffin
embedded capsule were stained with Masson's trichrome or hematoxylin and eosin (H&E)
for analysis. Images of the trichrome and H&E stained samples were collected using 4x, 10x
and 20x objectives on a Nikon Eclipse TE2000-U with a Nikon Digital Sight DS-2Mv
Digital Camera (Nikon Inc., Melville, New York).
Glucose Detection
All glucose samples were measured using a colorimetric glucose assay in a 96-well
microtiter plate format. Phosphate buffer (58.5 μL, pH 7.0) was added to each microtiter
plate followed by addition of either dialysate (3 μL) or varying volumes of a standard
glucose solution (1-3 μL) for a calibration curve. In the dark, a glucose assay mix (58.5 μL,
pH 7.0) containing glucose oxidase (17.2 U/mL), horseradish peroxidase (3.6 U/mL) and o-
dianisidine (0.43 mM) was added to each well and incubated at 37 °C for 1 h. After
incubation, 12 N sulfuric acid (80 μL) was added to end the reaction and intensify the color.
The absorbance of each well was measured using a Labsystems Multiskan RC microplate
reader (Helsinki, Finland) equipped with a 540 nm filter.
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Histological analysis was performed on tissue adjacent to probes functional ≥13 d of
implantation. Capsule thickness was measured from trichrome-stained tissue sample. The
foreign body capsule was defined as the region of inflammatory cells at the probe surface
and the dense collagen oriented parallel to the probe membrane. Two cross-sectional slides
per capsule were imaged with seven measurements of the capsule thickness per image and
averaged. Collagen density was calculated in four 400 × 100 μm2 fields from each of two
slides per probe using a previously developed MATLAB (The MathWorks, Natick, MA)
program that determines the percent collagen.10, 30 The inflammatory response as
determined by cell density was calculated by counting the nuclei between the dense collagen
and probe surface in four 50 × 100 μm2 fields from each of two slides per probe using a
MATLAB program.30, 31
RESULTS AND DISCUSSION
We and others have reported on the promising anti-infection efficacy of and wound healing
properties promoted by materials that spontaneously release NO.18, 19, 21 To date, the long-
term benefits of NO on in vivo sensor or probe response have not been determined despite
reduced capsule formation. Microdialysis studies allow for direct quantification of analyte
diffusion to the implant surface as a function of implant time, a critical parameter for
developing biocompatible in vivo sensors. In contrast to standard tissue histology, daily
monitoring is feasible as the tissue is not disrupted for analysis, thus requiring fewer animals
for a complete study. To evaluate the effect of NO release during the early stages of the
wound healing process, an appropriate method for delivering NO was determined.
An initial approach for achieving controlled NO release from a microdialysis probe focused
on perfusing small molecule NO donors. Unfortunately, the NO release kinetics from the
small molecule NO donors we employed was too rapid, resulting in irregular NO release and
even bubble formation in the syringe. Silica-based nanoparticles were also explored due to
their extended NO release, but we observed significantly larger probe failure rates attributed
to blocking of the probe and/or tubing by particles. Coating NO-releasing polyurethane
directly onto the membrane significantly diminished glucose recovery. We thus determined
that using saturated NO solutions provided steady, controlled NO release without
compromising the probe prior to implantation.
NO Release from Microdialysis Probes
A NO-saturated PBS solution introduced through the microdialysis probe at 2.0 μL/min
provided a constant NO flux during the perfusion period (Figure 1). An 8 h perfusion
window allowed time for the probes to be disconnected, reducing mechanical stress on the
percutaneous implants (mechanical stress has been shown to affect wound healing in
vivo)10. In PBS, we measure an average NO flux of 162 ± 18 pmol cm-2 s-1, corresponding
to a total release of 4.6 ± 0.5 μmol cm-2 per day over 14 d of implantation. By releasing NO
from the perfusate, we were able to compare the control and NO-releasing probes directly as
the membrane material contacting the surrounding tissue remained identical. While constant
noise in the NO flux originating from the syringe pump noise was noted, the observed signal
was always >3σ greater in magnitude (Figure 1).
The measured NO flux was significantly less than expected from the saturated NO solution
(1.9 mM NO). While a portion of the decreased NO flux may be attributed to incomplete
diffusion of the NO through the probe membrane, flow rate experiments indicated greater
loss through the gas permeable microdialysis probe tubing at reduced flow rates (data not
shown). To reduce NO loss, we attempted to replace the inlet tubing with gas-impermeable
PEEK tubing. Unfortunately, the stiffness of the PEEK tubing led to a greater rate of probe
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failure due to undesirable mechanical stress. Although the polyurethane resulted in lower
(~60%) NO flux, its use was necessary for enabling a robust set up, with levels of NO
similar to our previous NO-releasing xerogel materials that reduced the capsule formation in
vivo.
Glucose Recovery: In Vitro and In Vivo
Either the glucose concentration in the external solution (bench studies) or the blood glucose
concentration (in vivo) were used with the dialysate concentrations (Figure SI-1) to calculate
the EE using eq 1 and multiplied by 100 to obtain EE%. Blood glucose levels were used to
estimate the glucose concentration in subcutaneous tissue (Ce).32 The EE% for glucose of
probes in well-stirred in vitro solutions using PBS and PBS-NO was 70±5 and 71±5%,
respectively. The observed difference was not statistically significant and allowed for direct
comparison between the control and experimental microdialysis probes in vivo. While the in
vivo microdialysis flow rate employed (2 μL/min) may deplete local glucose more rapidly
than an implanted electrochemical sensor,27 the steady-state equilibrium established in vivo
at such a flow rate was necessary to quantify the wound healing response. As shown in
Figure 2, the EE% of NO-releasing probes remained constant over the 2 week implantation
while control probes suffered from diminished analyte diffusion after 7 d of perfusion. As
much prior work has noted that fibrous encapsulation diminishes diffusion of small analytes
to implant surfaces, our results may indicate a reduced capsule thickness and ultimately
improve sensor performance.33 Indeed, others have indicated that the lag in sensor response
time originates from greater resistance to mass transfer.34 Equally problematic, lowered
analyte diffusion through a highly resistive fibrous capsule may interfere with glucose and
oxygen levels at the sensor-tissue interface, thereby negatively affecting sensor
performance.35 Based on the EE%, we predict that NO-releasing glucose sensor membranes
would facilitate enhanced glucose diffusion over long implantation periods compared to
controls, and improve sensor performance. Such studies are currently underway in our
laboratory.
Histology Analysis
Wang et al. previously reported the encapsulation of their microdialysis probes in a rat
model after ~7 d.25 We thus hypothesize that the EE% difference between NO and control
probes is the result of decreased microdialysis probe encapsulation from NO release.
Histological analysis of the capsules surrounding NO-releasing and control probes is shown
in Figure 3. As expected, the thickness of the fibrous capsule surrounding the Masson's
trichrome-stained cross sections of control probes (Table 1) was greater than that measured
for the NO-releasing probes. The cross sections stained with H&E (Figure 3) also revealed
decreased inflammatory cell densities at the NO-releasing probe membranes relative to
controls, indicative of a mitigated FBR. Unexpectedly, the collagen density adjacent to NO-
releasing was greater than that adjacent to control probes.
The cause for increased collagen density is presently unknown. While we previously
reported a decrease in collagen density for NO-releasing xerogel membranes, others have
reported that NO at high concentrations increases collagen deposition in wound healing.18,
36-38 Of note, the xerogel system resulted in a burst of NO initially followed by
significantly less (~95%) NO release for ~3 d. In contrast the NO release levels used in this
study were equivalent to daily NO bursts for 8 h. Although improving glucose recovery and
reducing the initial FBR, our data indicates that intermittent NO bursts at large NO flux may
negatively impact long-term wound reconstruction. Koschwanez et al. have also reported
that percutaneous and subcutaneous implants behave differently, possibly due to mechanical
stresses.10 As well, we observed significant migration of the percutaneously-implanted
probes during our study, likely caused by animal movement and resulting stress from the
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microdialysis tubing. Such stress would augment the FBR to the implanted material. Future
studies should examine the effect of NO as a function of implant type (i.e., subcutaneous or
percutaneous). Furthermore, NO is a potent vasodilator,39 and the effect of blood flow
changes on glucose recovery using microdialysis probes is controversial.40-42 However, we
note that the glucose recovery in our model was not affected in the acute phase (< 7d) as a
function of NO release (Figure 2), indicating no effects due to NO-induced vasodilation.
While microdialysis allowed for daily NO release and subsequent analysis of the FBR,
probe failure remained a limitation. For example, total microdialysis probe failure rates were
~30 and 65% over 8 and 14 d, respectively. Using these methods, studies lasting ≥14 d
would likely suffer similarly high failure rates, regardless of NO release.
CONCLUSIONS
We demonstrated the benefits of in vivo NO release using microdialysis with respect to
glucose recovery and the FBR. The observed difference in EE% obtained from glucose
recovery data suggested improved tissue integration of the microdialysis probe. Histological
analysis indicated that the release of NO reduced both the capsule thickness and
inflammatory cell density at the surface. While the kinetics and total release of NO
employed are not yet achievable through conventional NO storage/release chemistries (e.g.,
NO donors), our results support the conclusion that NO release is a viable strategy for
mitigating the FBR and improving analyte diffusion to a sensor. Future work may determine
the optimal NO release flux and durations, and the concomitant effects of NO on long-term
tissue viability. By maintaining glucose diffusion to a subcutaneous implanted sensor, both
the sensitivity and response time may be enhanced circumventing previous FBR-mediated
limitations. Studies evaluating the effects of NO release on the analytical performance of in
vivo glucose sensors are currently underway.
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Representative daily NO release from a microdialysis probe over 8 h while flowing PBS-NO
at 2.0 μL/min.
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Glucose recovery at various times of implantation for the NO-releasing (filled, red) and
control (empty, black) probes. Error bars are ± standard error of the mean. Significant
differences (*) are p<0.05.
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Representative histology slides of cross sections stained with Masson's trichrome (A and C)
or hematoxylin and eosin (B and D) of NO-releasing (A and B) and control (C and D)
probes explanted at 14 d. Arrows in the hematoxylin and eosin stained pictures indicate the
probe membrane. Arrows in the Masson's trichrome stained pictures indicate the implant
site, surrounded by dark stained inflammatory cells and the collagen capsule. An increased
capsule size and inflammatory response at the membrane surface are observed at control
probes.
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Table 1
Results of histological analysis from both hematoxylin and eosin and Masson's trichrome stained slides.
Probe type Cell density (nuclei / 50 × 100 μm2) Capsule thickness (μm) Collagen density (%)
Control (n=5) 60.4 ± 8.9* 689 ± 61† 62 ± 6*
NO-releasing (n=4) 37.7 ± 6.6 599 ± 69 72 ± 4
*
Significantly different at p<0.05
†
Significantly different at p<0.10
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